Optimer’s Up For Sale, Fundamental Short is Off the Table
Insights - Optimer Pharma (OPTR) announced that along with the ousting of upper level management and appointment of an interim CEO, it’s putting the company up for … Continue Reading
Read nowAuthor Archives: Jake King
Solid Where it Matters: Questcor To Climb On Strong Quarter And Dividend Raise
Long Ideas - The Bears may focus on the pushes and pulls around Questcor Pharmaceuticals’ (QCOR) 4Q 2012 earnings results, but the bottom line is, the earnings results … Continue Reading
Read nowEndo Health To Become The Next Valeant – or Part of Valeant
Long Ideas - Endo Pharmaceuticals (ENDP) named its new CEO Monday morning, Rajiv De Silva, who was formerly President and COO of Valeant Pharmaceuticals (VRX). In a January … Continue Reading
Read nowSciClone’s Credibility Takes Another Hit, So Will The Stock
Most Popular - SciClone Pharmaceuticals (SCLN) is restating its financials from 2011 and the first nine months of 2012, an announcement that causes additional concern for this U.S.-based, … Continue Reading
Read nowFor Amedisys, Strong Headwinds Mean That Estimates and Stock Are Going Lower
Most Popular - The Home Health Services industry remains under pressure due to regulatory scrutiny and looming reimbursement cuts. As we have written in the past, Amedisys, Inc. … Continue Reading
Read nowNo Major Earnings Surprises, but InterMune is Cash-Rich and An Interesting Trade
Long Ideas - A month after raking in more than $225M through a combination of debt and equity sales, InterMune’s (ITMN) 2012 financial results released Thursday contain little … Continue Reading
Read nowSteer Clear of OPTR’s Short And Long-Term Risks
Research - The hope remains alive that Optimer (OPTR) will somehow power through a disappointing launch and increase prescription growth sufficiently to offset the 25% discount that … Continue Reading
Read now